![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sky Capital Announces Clinical Trial Approval for AST
Sky Capital Announces Clinical Trial Approval for AST
May 10, 2005
Sky Holdings, listed on the AIM market of the London Stock Exchange, announced that its 18 percent owned investment, Advanced Spinal Technologies (AST), has received approval from the Western Institutional Review Board to commence clinical trials for its Technology-Assisted Micro-Mobilization and Reflex Stimulator (TAMARS) -- previously known as the pamm3 MicroManipulator. AST holds the exclusive license to the intellectual property and commercial rights relating to TAMARS in the U.S., Europe, Australia, Japan and all other countries of the world other than the UK and the Republic of Ireland.
mysan.de (http://www.mysan.de/article99972.html)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct